ARCHIVES

Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment

This article is from The Cancer Letter archive.

Vol. 40 No. 06 | February 7, 2014

Download PDF Visit The Full Archive

Related Articles

NCI To Place 20% Cap On Grant Renewal Increases.

May 25, 2001

In Brief: New Contract To Speed Drug Development Planned; Groups To Get $5.6 Million Extra

February 27, 1976

Study Finds Comparable Accuracy For Virtual And Standard Colonoscopy

September 26, 2008

Key Cancer Legislation Remains Unfinished as Congress Departs for Election.

October 6, 2006

Stem Cell Transplant More Effective than Chemotherapy

April 25, 2003

Reinventing NCI: Clinical Trials System Changes Not Easy Or Quick, Klausner Says; NCAB Members, Others, Sound Off On Group’s Report

October 10, 1997